Список литературы к Главе 11

54. Cramer P. et al. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2­BAG): primary endpoint analysis of a multicentre, open­label, phase 2 trial // Lancet Oncol. 2018. Vol. 19, N 9. P. 1215–1228.

55. Collett L. et al. Assessment of ibrutinib plus rituximab in front­line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial // Trials. 2017. Vol. 18, N 1. P. 387.

56. Jain P. et al. Long­term follow­up of treatment with ibrutinib and rituximab in patients with high­risk chronic lymphocytic leukemia // Clin. Cancer Res. 2017. Vol. 23, N 9. P. 2154–2158.

57. Cramer P. et al. CLL2­BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia // Future Oncol. 2018. Vol. 14, N 6. P. 499–513.

58. Cramer P., von Tresckow M., Robrecht S., Bahlo J., Al­Sawaf O., Langerbeins P. et al. Bendamustine followed by ofatumumab and ibrutinib in patients with chronic lymphocytic leukemia (CLL): CLL2­BIO trial of the German CLL Study Group (GCLLSG) // Blood. 2017. Vol. 130. P. S494–S1494.

59. Fraser G. et al. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma // Leukemia. 2019. Vol. 33, N 4. P. 969–980.

60. Davids M.S. et al. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single­arm, multicentre, phase 2 trial // Lancet Haematol. 2019. Vol. 6, N 8. P. e419–e428.

61. Michallet A.­S., Dilhuydy M.S., Fornecker L.M., Tournilhac O., Ysebaert L., Delmer A. et al. A time­limited treatment with ibrutinib along with a reduced number of immunochemotherapy courses leads to profound and long­lasting responses in previously untreated CLL patients // EHA Library. 2020. 12 Jul. P. S160.

62. Roberts A.W. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia // N. Engl. J. Med, 2016. Vol. 374, N 4. P. 311–322.

63. Stilgenbauer S. et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open­label, phase 2 study // Lancet Oncol. 2016. Vol. 17, N 6. P. 768–778.

64. Wierda W.G. et al. Minimal residual disease status with venetoclax monotherapy is associated with progression­free survival in chronic lymphocytic leukemia // Blood. 2018. Vol. 132, suppl. 1. P. 3134–3134.

65. Seymour J.F. et al. Venetoclax­rituximab in relapsed or refractory chronic lymphocytic leukemia // N. Engl. J. Med. 2018. Vol. 378, N 12. P. 1107–1120.

66. Kater A.P. et al. Fixed duration of venetoclax­rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post­treatment follow­up of the MURANO phase III study // J. Clin. Oncol. 2019. Vol. 37, N 4. P. 269–277.

67. Kater A.P. et al. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL // Blood Adv. 2018. Vol. 2, N 24. P. 3566–3571.

68. Huber H., Edenhofer S., von Tresckow J., Grimm M., Zhang C., Robrecht S. et al. CLL2­GIVe, a prospective, open­label, multicenter phase II trial of obinutuzumab (GA101, G), ibrutinib (I), plus venetoclax (VE) in untreated patients with CLL with 17p deletion/TP53 mutation // EHA Library. 2020. 12 Jul. P. S157.

69. Lampson B.L. et al. Preliminary safety and efficacy results from a phase 2 study of acalabrutinib, venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia (CLL) // Blood. 2019. Vol. 134, suppl. 1. P. 32.

70. Bosch F. et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or re­ lapsed chronic lymphocytic leukaemia // Br. J. Haematol. 2002. Vol. 119, N 4. P. 976–984.

71. Bosch F. et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication // Clin. Cancer Res. 2008. Vol. 14, N 1. P. 155–161.

72. Bosch F. et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia // J. Clin. Oncol. 2009. Vol. 27, N 27. P. 4578–4584.

73. Strati P. et al. Eradication of bone marrow minimal residual disease may prompt early treatment dis­ continuation in CLL // Blood. 2014. Vol. 123, N 24. P. 3727–3732.

74. Dreger P. et al. Allogeneic stem cell transplantation provides durable disease control in poor­risk chronic lymphocytic leukemia: long­term clinical and MRD results of the German CLL Study Group CLL3X trial // Blood. 2010. Vol. 116, N 14. P. 2438–2447.

75. Chanan­Khan A. et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double­blind, phase 3 study // Lancet Oncol. 2016. Vol. 17, N 2. P. 200–211.

76. von Tresckow J. et al. CLL2­BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia // Leukemia. 2019. Vol. 33, N 5. P. 1161–1172.

77. Davids M.S. et al. Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) as Frontline Therapy for Younger CLL Patients. Washington, DC : American Society of Hematology, 2016.

78. Rogers K.A. et al. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia // Blood. 2018. Vol. 132, N 15. P. 1568–1572.

79. Porter D.L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia // Sci. Transl. Med. 2015. Vol. 7, N 303. P. 303ra139.

80. Gauthier J. et al. Comparison of efficacy and toxicity of CD19­specific chimeric antigen receptor T­cells alone or in combination with ibrutinib for relapsed and/or refractory CLL // Blood. 2018. Vol. 132, suppl. 1. P. 299.

81. Gill S.I. et al. Prospective clinical trial of anti­CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia shows a high response rate // Blood. 2018. Vol. 132, suppl. 1. P. 298.

82. Siddiqi T. et al. Rapid MRD­negative responses in patients with relapsed/refractory CLL treated with Liso­Cel, a CD19­directed CAR T­cell product: preliminary results from transcend CLL 004, a phase 1/2 study including patients with high­risk disease previously treated with ibrutinib // Blood. 2018. Vol. 132, suppl. 1. P. 300.

83. Moreno C. et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia // Blood. 2006. Vol. 107, N 11. P. 4563–4569.

84. Fischer K. et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group // J. Clin. Oncol. 2012. Vol. 30, N 26. P. 3209–3216.

85. Pettitt A.R. et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial // J. Clin. Oncol. 2012. Vol. 30, N 14. P. 1647–1655.

86. Santacruz R. et al. The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first­line therapy // Haematologica. 2014. Vol. 99, N 5. P. 873–880.